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Abstract
Background: Human papillomavirus detection is very important for the evaluation of prevention
strategies in cervical cancer. In the Azorean population, the virus prevalence has never been
studied, and there is no data available to preview a successful outcome with HPV vaccination. In
this article, our objective is to characterise the HPV genotypes in Terceira Island, contributing for
the epidemiological knowledge on the virus infection.
Results: Cervical samples were collected from 289 women aged 16–81 in the Gynaecological
Outpatient Clinic of the Hospital de Santo Espírito de Angra do Heroísmo (HSEAH). HPV DNA
was amplified by Polymerase Chain Reaction using the general consensus primers PGMYO9/
PGMY11. Commercially available Papillomavirus Clinical Arrays® kits (Genomica) were used to
perform HPV genotyping. 30 women were HPV positive, with a median age of 41 years old. Our
results show that the overall HPV prevalence was 10.49%. Seventeen genotypes were identified,
including 58.82% high risk, 17.65% low risk and 23.53% undetermined risk.
Conclusion: Unlike other epidemiological studies, HPV31 was the most frequent type (26.67%) in
Terceira Island, followed by HPV16 (10.00%), HPV51, HPV53, HPV70 and HPV82 (6.67%). Further
studies are needed to investigate if the HPV types found in our population are associated with the
risk of progression to high-grade squamous intraepithelial lesions or cervical cancer.
Background
Human Papillomavirus (HPV) is the main responsible of
one of the most common sexually transmitted diseases
worldwide and persistent infection is the major risk factor
for the development of cervical cancer.
To date, more than one hundred genotypes have been
identified and 40 types are sexually transmitted and infect
the cervix [1,2]. Most cervical infections are transient and
cause either no detectable or mild pathological changes,
but in some instances, infections persist and can progress
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over the course of several years to cervical intraepithelial
neoplasia (CIN), and then possibly to invasive cervical
cancer.
Detailed epidemiological studies of HPV infection, CIN
and progression to cancer have tailored which are the
most frequent types playing a key role in cervical carcino-
genesis (high risk types), and optimal strategies are been
designed to prevent, via HPV screening and vaccination,
the approximately 200,000 deaths caused by this disease
annually worldwide [1].
Epidemiological studies on the prevalence of HPV types in
cervical cancer show that 50% of all cases are related to
HPV 16. The others are associated mainly with HPVs 18,
45, 31, 33, 52, 58 and 35, including infections with both
single and multiple types [3].
In the European Union, there were over two million inci-
dent cases of cancer in 2006 and over one million cancer
deaths. In women, breast cancer was the most common
form of cancer, followed by colorectal cancer and there
were 82 500 (8.0%) cases of cervical cancer [4]. Portugal
has a relatively high incidence of cervical cancer in the
European Union, and the high frequency of HPV-16 infec-
tion is in concordance with other white populations [5].
Cervical cancer is largely preventable through cytological
screening programs designed to facilitate the detection
and treatment of immediate precancerous lesions. These
evaluations require trained cytotechnologists and up to
three visits for screening [6]. Alternative methods such as
DNA testing for human papillomavirus, especially high-
risk types, are becoming increasingly attractive as a pri-
mary screening tool, because of sensitivity and cost-effec-
tiveness [7].
Despite the fact that prevalent HPV types are almost the
same in all regions of the world, it is important to improve
HPV genotype characterisation worldwide, including
under-reported regions such as the population of the
Azores, helping to define preventive strategies better.
The aim of this study is to participate in the global effort
to characterise HPV genotypes, contributing for the fulfil-
ment on the epidemiology of HPV infection.
Methods
Study population
A total of 289 women with a median age of 41 years
(range 16 to 81 years) participated in this study between
February 2006 and January 2007. The population was
consecutively recruited from the Gynaecology Outpatient
Clinic at the Department of Obstetrics and Gynaecology
of the Hospital de Santo Espírito de Angra do Heroísmo
(HSEAH). The Ethics Committee of Hospital de Santo
Espírito de Angra do Heroísmo, approved the study pro-
tocol.
Sample collection
Sample material was rinsed into a liquid medium (Pre-
servCyt, Cytyc Corporation), transported to Serviço Espe-
cializado de Epidemiologia e Biologia Molecular
(SEEBMO) of HSEAH and stored at 4°C before DNA
extraction.
DNA extraction and purification
The DNA from cervical samples was extracted and puri-
fied, using Papillomavirus Clinical Arrays® (Genomica)
kit, according to the manufacturer's instructions. Briefly,
after 1 ml cell suspension centrifugation (10 minutes, 12
000 rpm, room temperature), the lysis buffer and the pro-
teinase K (20 mg/ml) were added on the pelleted cells and
incubated 2–3 hours ate 56°C in a Thermomixer Comfort
Eppendorf. After 10 minutes proteinase K inactivation
period at 70°C, DNA purification was performed, using
DNA purification columns and the pelleted DNA was
resuspended in 100 μl Elution Buffer.
Polymerase chain reaction (PCR)
The amplification reaction was carried out in a total vol-
ume of 50 μl, containing 5 μl of extracted DNA and 45 μl
of a PCR mix with PGMYO9/PGMY11 generic consensus
primers. The PCR mix contains, beside the generic consen-
sus primers, two internal controls that will validate each
sample genotyping: genomic DNA control and amplifica-
tion control. The first control consists in a primer set that
amplifies a 892 bp CFTR gene fragment and the second
control amplifies 1202 bp of a modified plasmid, using
the same primers as the CFTR gene.
The mixture was submitted to 45 cycles of amplification,
using a DNA thermalcycler T-Gradient (Biometra). Each
cycle included a denaturation step at 94°C for 30 seconds,
followed by an annealing step at 55°C for 1 minute and a
chain elongation step at 72°C for 90 seconds. Each PCR
was initiated with a 9 minutes denaturation step at 95°C
and finished by an 8 minutes extension-step at 72°C.
Different laboratory areas were used for sample handling
(pre-PCR area), product amplification (PCR area) and
HPV genotyping (post-PCR area).
HPV testing
The commercially available Papillomavirus Clinical
Arrays® (Genomica) kit was used for HPV DNA genotyp-
ing. All samples were analysed for the presence of he fol-
lowing HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70,
71, 72, 73, 81, 82, 83, 84, 85 and 89.Infectious Agents and Cancer 2008, 3:6 http://www.infectagentscancer.com/content/3/1/6
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HPV detection was conducted using PGMYO9/PGMY11
general consensus primers designed to amplify a 450 bp
HPV L1 gene fragment. This region is used because it is
highly conserved between different HPV types but has suf-
ficient variation for the identification of each one [2].
The detection of the amplified PCR product was per-
formed with a new technological platform using a low
density Microarray, anchored in 2 ml tube-AT tube. It
allows simultaneous detection of multiple molecular
markers in the L1 fragment of 35 different HPV types and
in the necessary controls to insure a feasible assay. All
process was followed according to the manufacture's
standard protocol.
PCR products were marked with biotin and, after amplifi-
cation, they hybridised with the respective probes in spe-
cific known AT tube areas. Biotin binds to streptavidin-
peroxidase after incubation. The addition of the TMB sub-
strate (3,3',5,5'-tetrametilbinzidine) generates an insolu-
ble product after hybridisation.
The results were processed by software, which allows
detection, interpretation and reporting for each sample.
Results
The study encompasses two hundred and eighty nine
women with a mean age of 41 years and was stratified in
5-year age groups.
Two hundred and seventy five (95.2%) women had nor-
mal cytology. Epithelial cell abnormalities were detected
in 14 women: 4 were labelled as atypical squamous cell of
undetermined significance (ASCUS; 1.38%), 7 had cervi-
cal intraepithelial neoplasia (CIN; 2.42%), and 3 women
(1.04%) had been treated for cervical carcinoma and were
excluded from the study sample. The three exclusion cases
were HPV positive: HPV16, HPV61 and 66 and HPV58.
HPV-DNA was detected in thirty (10.49%) out of tow
hundred and eighty six eligible women and only one had
cytological abnormalities (CIN).
Figure 1 shows the age distribution of population under
investigation, discriminating HPV positive and negative
women; two peaks in age groups 25 to 34 and in 40 to 54
years old are clearly in evidence. Women younger than 25
years and older than 59 years had a lower HPV prevalence.
Seventeen HPV types were detected, encompassing three
low-risk types (17.65%) – including a double low risk
infection, ten high-risk types (58.82%), and four undeter-
mined risk types (23.53%).
Single infections were found in 26 women (86.67%) and
multiple infections were detected in 4 (13.33%), ranging
from 2 to 3 different genotypes (average of 1.17 types per
women).
The most common types of Human Papillomavirus in
Terceira Island were HPV31, followed by HPV16, HPV51,
HPV 53, HPV70 and HPV82 (Figure 2).
Discussion
In the present study, we intended to evaluate the preva-
lence of different HPV type infection in a sample of
women from the Azorean population. Among those
referred to a Gynaecologic Outpatient Clinic, the preva-
lence of HPV infection in the Azorean population
(10.49%) was concordant with the range of 2 to 44%
world-wide [8].
Burchell et al showed that age-specific HPV prevalence
among women with normal cytology was highest for
younger women (<20) and decreased in the middle age
groups, to increase again at age 65 and older [9]. This find-
ing is not concordant with our results were HPV preva-
lence was highest between 25 and 34 years old and in
middle age groups (40 to 54 years old) (Figure 1). Regard-
ing older women, there were no women on age groups 75
to 79 years old, but HPV infection decreased from 60 to 84
years old in our sample.
The second major peak of infection identified in our pop-
ulation, as described in other studies, was in the peri- or
post-menopausal years. Although the reason for this
"menopausal peak" is still unclear, it may be related to the
reactivation of latent infections acquired earlier in life,
due to a gradual loss of type-specific immunity or to
acquisition of new infections by sexual contacts with new
partners later in life [8,9].
Age-distribution in HPV-positive and HPV-negative women Figure 1
Age-distribution in HPV-positive and HPV-negative 
women.
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The most common HPV types in Clifford et al meta-anal-
ysis, in either single and multiple infections, were HPV16,
HPV 42, HPV 58, HPV 31, HPV 18, HPV 56, HPV 81, HPV
35, HPV 33 and HPV 45 [7].
In our sample, the majority of HPV-positive women were
infected with the high-risk HPV 31 – 26.67% (Fig. 2),
which has a distribution of 9%, 7%, 5% and 4% in
Europe, Sub-Saharan Africa, South America and Asia,
respectively, according to the Clifford study.
Rates of HPV-16 infected women in Azores (10.00%)
were quite similar to those in Asia (14%) and much lower
than in Europe (21%).
HPV18 infection among women was very similar across
all world regions, varying from 4 to 5%; slightly lower
results were obtained in the Azores population (3.33%).
The discrepancy between our data and previous European
publications may be related to important influxes of
groups coming from Europe; especially Eastern Europe
(Ukraine and Russia), Africa (Cabo Verde), Latin America
and North America.
Prevention of HPV infection through vaccination is
expected to dramatically reduce the morbidity and mor-
tality associated with HPV infection. These vaccines are
based on the major capsid protein of the virus, L1 pro-
teins, which are capable of self-assembling into virus like
particles (VLPs) when expressed in cells. These VLPs share
great similarity to native HPV virions, are non-infectious
and non-oncogenic and can induce high levels of neutral-
izing antibodies [10,11].
Two vaccines are currently available and they incorporate
HPV types more frequently associated with cervical can-
cer. A bivalent VLP vaccine (Cervarix™ GlaxoSmithKline)
is composed of the assembled VLPs of HPV16 and HPV18
L1, and a quadrivalent VLP based vaccine (Gardasil®
Merck & Co) that includes HPV16, HPV18, HPV6 and
HPV11; these last two types cause the majority of genital
warts (approximately 90%) in both men and women
[10].
The proportions of high-risk HPV infections preventable
by a vaccine for HPV16 and HPV18 vary by region, being
highest in Europe and lowest in Sub-Saharan Africa [12].
However, the available vaccines do not contain HPV31,
which is prevalent in the Azorean population.
Determining whether any significant protection is pro-
vided between genotypes will be a prerequisite to increase
the breadth of genotype coverage for prophylactic vac-
cines. If VLP vaccines are found to confer a high rate of
type-specific protection but no significant cross-protec-
tion, alternative second-generation vaccines may be
needed to protect against other high risk HPV types, such
as HPV45 and HPV31, to perform a major reduction in
cervical cancer [13].
Conclusion
Future studies are necessary to confirm some study issues.
It is extremely important to enlarge our sample in order to
confirm the very high HPV31 prevalence not only in nor-
Human Papilomavirus type distribution Figure 2
Human Papilomavirus type distribution.
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mal cytology but also in high-grade lesions and in cervical
cancer.
These findings will let us know about the efficacy of the
existing vaccines and if a new one should be tailored for
the population under investigation.
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